Medical devices biocompatibility assessment on HCE by VitroScreen

24 May 2019

Evidences of delayed cytotoxicity of preserved compared to preservative free eye drops

The approach  proposed in the article opens a new frontier in the risk assessment of all type of liquid  formulations that  have a direct  acute and repeated contacts with the eye.

A multiple endpoint analysis (MEA) approach on human reconstructed corneal epithelium (HCE) model has been applied to assess the biocompatibility (cytotoxicity and irritation potential) of medical devices (MD): ophthalmology literature clearly shows the need to better assess these products to exclude any potential chronic damage to the ocular surface.

Preserved eye drops (Artelac Multidose, Optive multidose and Artelac Rebalance Multidose) and the same without preservative (Artelac Edo, Optive Unidose, Artelac Rebalance Unidose) and Thealoz Duo were tested after acute (24 h + 16 h post incubation) and repeated (2 applications/day for 72 h) exposure using BAK 0.01% as positive control on HCE.

Cellular viability, trans-epithelial electrical resistance measurements, LDH release and occludin gene expression were evaluated for each product to discriminate the potential toxicity of preservatives. The BAK 0.01% toxicity on HCE was confirmed following both exposures. The analysis of the same parameters reveals that the 72 h exposure was suitable to identify toxicity and damages to the ocular surface even for ‘soft’ preserved MD.

The results confirm the reliability, sensitivity and predictivity of the MEA on HCE in detecting subclinical signs of cellular toxicity: ‘soft’ preservatives resulted toxics suggesting that delayed toxicity should be integral part of the biocompatibility assessment of ophthalmic formulations intended for long-term use.

read more: Vitroscreen Medical Devices HCE 2019

Company Profile

 

vitroscreen.2.logo_1 

Contact

Please for more information contact

20149 Milano

 www.vitroscreen.com


Save time and easily find the methods and the testing suppliers to substantiate your actives and cosmetics claims.

Don't miss our weekly newsletter

* Receive regular news of what's moving the world of preclinical and clinical testing of the Beauty industry

Save time and easily find the methods and test providers to validate your product claims.